United States Induced Pluripotent Stem Cell Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Takara Bio Inc., Fate Therapeutics, BlueRock Therapeutics LP, Aspen Neuroscience, and Ncardia

Induced Pluripotent Stem Cell Market is reached US$ 1.98 Billion in 2024 from US$ 1.81 Billion in 2023 and is expected to reach US$ 4.66 Billion by 2033, growing at a CAGR of 10.1% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Induced Pluripotent Stem Cell Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/induced-pluripotent-stem-cell-market?sg

Key Players: Thermo Fisher Scientific Inc., REPROCELL Inc., FUJIFILM Cellular Dynamics, Axol Bioscience Ltd., Evotec, Takara Bio Inc., Fate Therapeutics, BlueRock Therapeutics LP, Aspen Neuroscience, and Ncardia.

USA - Industry Latest News 2025:

✅ 11 Jun 2025 - iXCells Biotechnologies launched the iPSCoreTM platform, a modular system to generate highly-characterized iPSC-derived human cell models for drug discovery and custom cell products.

✅ 11 Jun 2025 - Fate Therapeutics (San Diego) released updated clinical/preclinical data for its iPSC-derived product candidates (e.g., FT819/FT836 programs), highlighting progress in off-the-shelf iPSC-derived cell therapies and master iPSC bank activities.

✅ 05 Apr 2025 - I Peace, Inc. (Palo Alto) launched personalized iPSC production & banking services and longevity/rejuvenation offerings in the U.S., and announced off-the-shelf GMP iPSC lines earlier in 2025.

✅ 09 Jul 2025 - The Jackson Laboratory and New York Stem Cell Foundation announced a landmark alliance (JAX to assume NYSCF operations / assets) to combine genomics, mouse models and stem-cell platforms - a major institutional consolidation impacting iPSC research capacity in the US. (announced July; closing/complete steps reported later in 2025).

Japan - Industry Latest News 2025:

✅ 29 Jul 2025 - A Japanese startup (Kyoto-based iHeart Japan) reported a clinical transplant of an iPSC-derived cardiac muscle cell sheet into a patient with heart muscle disease - an example of Japan's continued clinical translation of iPSC cardiac products.

✅ Throughout 2025 (various dates) - Healios K.K. continued advancing iPSC-derived NK and other cell therapy programs (presentations, manufacturing agreements and pipeline updates) and remains a visible commercial developer of iPSC-derived therapeutics in Japan.

✅ Ongoing / institutional - iPS Academia Japan (CiRA spin-outs / licensing activities) and Kyoto research teams continued publishing/announcing translational progress from donor-derived/allogeneic iPSC trials (Kyoto trials and collaborations noted in 2025 reports).

Korea - Industry Latest News 2025:

✅ 13 May 2025 - YiPSCELL (Korea) launched/administered an iPSC-derived osteoarthritis clinical program (injectable 3-D iPSC-derived cartilage spheroids in a joint trial with Seoul Saint Mary's / local institutions).

✅ 2025 (research & manufacturing updates) - Korean groups continued to publish and register iPSC-derived lines and clinical/characterization studies (academic iPSC line generation and translational work remain active in 2025).

Europe - Industry Latest News 2025:

✅ 18 Mar 2025 (interim result reported March 2025) - Xintela (Sweden) reported positive interim clinical data from its knee osteoarthritis study (XSTEM) showing safety and encouraging efficacy (pain/function improvement) at follow-ups (18 months / extended follow-up updates later in 2025).

✅ 29 Sep 2025 (announced Sep 29) - Cell X Technologies and BioLamina announced a collaboration to integrate defined laminin reagents with automated cell-processing (Cell X's CelligentTM) to improve reproducibility/standardization in iPSC-based manufacturing - a notable Europe/US cross-regional standardization effort (news item affects European reagent/standard-supply chain).

Growth Forecast Projected:
The Global Induced Pluripotent Stem Cell Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Induced Pluripotent Stem Cell Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=induced-pluripotent-stem-cell-market?sg

Key Segments:

By Type (Human iPSCs, Mouse iPSCs)

By Application (Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Induced Pluripotent Stem Cell producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Induced Pluripotent Stem Cell revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/induced-pluripotent-stem-cell-market?sg

FAQ's

Q1: What is the current size of the Induced Pluripotent Stem Cell Market?

A: The Induced Pluripotent Stem Cell Market stood at US$ 1.98 Billion in 2024 and is set to experience remarkable growth, reaching US$ 4.66 Billion by 2033

Q2: How fast is the Induced Pluripotent Stem Cell Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 10.1% from 2025-2033

Q3: Which regions are dominating the Induced Pluripotent Stem Cell Market and which are fastest-growing?

A: North America is expected to dominate the global induced pluripotent stem cells market with a 42.32% share in 2024.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/induced-pluripotent-stem-cell-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?sg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.